SAB BIO

SAB BIO is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat and prevent immune and autoimmune disorders. Founded in 2014, the company is traded on NASDAQ under the ticker symbol SABS. Their unique platform allows them to produce human, multi-targeted, high-potency immunoglobulins (IgGs) without the need for human donors or convalescent plasma. This innovative approach is being utilized to develop SAB-142, a potentially disease-modifying therapy for type 1 diabetes (T1D), which aims to delay the onset and progression of the disease by targeting the underlying cause of the immune system attacking insulin-producing cells.

SAB BIO has conducted seven clinical trials to date, demonstrating a strong safety profile for their platform. The company's commitment to research and development, coupled with their innovative platform and pipeline of promising candidates, positions them as a leader in the field of immunotherapies.

SAB BIO is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat and prevent immune and autoimmune disorders. Their unique platform enables the production of human, multi-targeted, high-potency immunoglobulins without the need for human donors or convalescent plasma. They are currently focused on developing SAB-142, a potentially disease-modifying therapy for type 1 diabetes, which aims to delay onset and progression of the disease. Their goal is to change the lives of people impacted by type 1 diabetes and other immune and autoimmune disorders by providing innovative treatments that address the underlying cause of these conditions.

SAB BIO promotes a culture focused on innovation and collaboration, driven by a shared commitment to addressing pressing health challenges. The company values scientific excellence, a patient-centric approach, and a strong work ethic, fostering an environment where diverse perspectives are encouraged and employees feel empowered to contribute to the company's mission.